Neurogene reaffirms Embolden data for 2H 2027, cash runway into Q1 2029Nov 17M&AAstraZenecaIdexx Laboratories Inc /DeUpdated
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
FDA lifts clinical hold on Arbutus's AB-101 IND applicationOct 22Regulatory decisionArbutus Biopharma Corplinezolid
Genentech's mycophenolate pregnancy registry listed as completed, last updated October 2026Oct 16Weekly roundup, 4 itemsAmneal Pharmaceuticals, LLCastegolimabUpdated
Pfizer wins two FDA labeling supplements; obesity trial roster unchangedOct 15Weekly roundup, 8 itemsberobenatidemethotrexate
Viatris to acquire Pacira BioSciences for $36.50 per share in cashOct 8M&APacira Pharmaceuticals, IncViatris Inc.
FDA approves labeling supplement for Mylan's Amnesteem (isotretinoin)Sep 15Regulatory decisionisotretinoinViatris Inc.
Viatris registers Phase 4 abuse-potential trial of gabapentin plus oxycodoneSep 10Trial updategabapentinoxycodone
Viatris: Ocuphire trial results posted, Amnesteem label update, gabapentin abuse study completedAug 21Weekly roundup, 3 itemsalprazolamgabapentin
Mylan wins FDA approval for labeling supplement on metformin ER tabletsAug 11Regulatory decisionmetforminViatris Inc.
Viatris raises 2026 guidance, reports FDA approvals and Tyrvaya sale in Q2 updateAug 6Quarterly updatevareniclineViatris Inc.
Mylan gets ANDA labeling supplement approved for fenofibrate tabletsAug 5Regulatory decisionfenofibrateViatris Inc.
Viatris-collaborated trial registered comparing Yupelri/Perforomist combo to standard COPD therapyJul 23Trial updateformoterolrevefenacin
Mylan doxepin label update approved; Viatris-linked contact lens comfort trial begins recruitingJul 16Weekly roundup, 2 itemsdoxepinViatris Inc.